Metsera Reports Second Quarter 2025 Financial Results and Pipeline Update

Summary

Metsera, Inc. reported second-quarter 2025 financial results, showing a net loss of $68.7 million for the quarter and $145.3 million for the six months ended June 30, 2025. The company's cash position stood at $530.9 million as of June 30, 2025, which is expected to fund operations into 2027. Metsera also provided updates on its clinical pipeline, with positive Phase 1 data for its amylin candidate MET-233i and ongoing Phase 2b trials for its GLP-1 receptor agonist MET-097i.